Sign up
RZLT

Rezolute Inc (NASDAQ: RZLT)

Healthcare · Biotechnology

$4.25+0.24 (+5.85%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. RZLT rose 5.85% in the Nov 18 session to $4.25. The borrow fee is 0.49%. Nine active firms cover the stock as of Nov 19, 2026; eight active firms with targets average $10.13 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 50.1 (overbought above 70, oversold below 30)

Trend—

—

Short interest30.4% of float

FINRA settlement Oct 30, 2026

RZLT price chart

Price $4.25 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$3.98Nov 18, 2026 session
Previous close
$4.02Nov 17, 2026 close
Day range
$3.91 – $4.30Nov 18, 2026 session
52-week range—
Volume
2.93MNov 18, 2026 session
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

RZLT · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

— · Quantellect signals not available

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

Buy

0Strong Buy
9Buy
0Neutral
0Sell
0Strong Sell

Based on 9 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$6.00
Average$10.13
High$15.00

As of Nov 19, 2026 across 8 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q1 2026−$0.18−$0.18—
Annual 2026—−$0.75—
Q3 2026−$0.17−$0.16—
Q2 2025—−$0.22—
Q1 2025—−$0.18—
Annual 2025—−$0.98—
Q3 2025—−$0.27—
Q2 2024−$0.26−$0.22—

Smart-money activity

— · Smart-money activity not available

All smart-money activity →

News and press releases

All RZLT news →

Company profile

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.

CEO
—
Headquarters
Redwood City, CA, United States
Employees
58
IPO date
May 1, 2014
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.